One biotech company put the mission of this week’s Exponential Medicine Conference to work by proving that is is possible to deliver real-time, accurate DNA testing. Exponential Medicine is a unique four-day conference that gathers world-class faculty, innovators and entrepreneurs from across the biomedical and technology spectrum to “explore the convergence of fast moving technologies.” [Read more…]
CDI Launches Opsis, Provia Expands Perinatal Storage, CCBC Gets Biologics License
We have released coverage of this week’s stem cell industry activity that I am excited to share with you. It was a major week for stem cells, with CDI launching Opsis Therapeutics, Provia Laboratories expanding its stem cell product portfolio, CCBC getting a FDA Biologics License for CLEVECORD™, STEMCELL Technologies exploring genomic instability in an upcoming webinar, and iPSCs turning 10. [Read more…]
Cellular Dynamics International (CDI) Launches Opsis Therapeutics to Develop Cell Therapies for Retinal Diseases
MADISON, WIS, September 28, 2016 – Cellular Dynamics International, Inc. (CDI), a FUJIFILM company and the leading developer and manufacturer of induced pluripotent stem cell (iPSC) products, today announced a new venture, named Opsis Therapeutics. Formed on July 31, Opsis Therapeutics is focused on discovering and developing novel medicines to treat patients suffering from retinal diseases. [Read more…]
Top 10 iPSC Talks from Axiogenesis’ American User Symposium
Axiogenesis hosted an American user symposium titled, “iPSC Derived Cells & Assays Come of Age.” Held in Boston, Massachusetts (June 13, 2016), the symposium explored how experts in the pharmaceutical industry and academia use Axiogenesis’ cells and assays within drug discovery, safety/toxicology screening, and bioengineering applications.
It also presented current approaches to establish and define standards for these cellular models. Widely attended by representatives from the pharmaceutical sector, symposium attendees had the valuable opportunity to view case studies of iPSC-derived cells utilized in drug development decision-making and biomedical research.
To capture highlights from the event and facilitate thought-provoking conversation, below is a list of the top 10 talks from the recent Axiogenesis’ iPSC user symposium. [Read more…]
UK Regulatory Authority Approves Cynata Therapeutics’ Phase I GvHD Clinical Trial
- UK regulatory authority MHRA approves Phase 1 trial with Cymerus(TM) MSCs
- World first clinical trial with allogeneic iPSC-derived product
- Major milestone for stem cell therapeutics and regenerative medicine
- Cements Cynata’s global leadership in second generation MSC therapeutics
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 68
- Next Page »